Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
4,998.60 -73.03 (-1.44%) Dow
37,809.08 -651.84 (-1.69%) Nasdaq
15,408.26 -304.49 (-1.94%) Bitcoin USD
63,353.33 -2,632.41 (-3.99%) CMC Crypto 200
1,371.39 -11.18 (-0.81%)
Evotec SE (EVO)
| Previous close | 5.2300 |
| Open | 5.1900 |
| Bid | 3.6400 x 200 |
| Ask | 6.4200 x 200 |
| Day's range | 4.9750 - 5.1100 |
| 52-week range | 4.9750 - 13.4900 |
| Volume | |
| Avg. volume | 76,929 |
| Market cap | 1.768B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.20 |
Simply Wall St.Evotec Full Year 2023 Earnings: EPS Misses Expectations
Evotec ( ETR:EVT ) Full Year 2023 Results Key Financial Results Revenue: €781.4m (up 4.0% from FY 2022). Net loss...
BenzingaLife Science-Focused Evotec Shares Plunge To 6 Year Lows On Gloomy Annual Forecast
European life science company Evotec SE (NASDAQ:EVO) announced a priority reset to optimize its business to meet evolving market demand and focus on profitable growth in 2024 and beyond. The company is focusing on and rightsizing organizations to overcome the challenging market environment and return to sustainable and profitable growth. Shared R&D and Just–Evotec Biologics will replace EVT Execute & EVT Innovate segments in a streamlined reporting structure as of Q1 2024. The priority reset is
PR NewswireEVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
